Since many decades basis of research for the detection of the cancer biomarkers is opted by many researcher to identify new drug for cancer. Specific biomarker assessment for the cancer will help in the diagnostic approach for the cancer diagnosis along with the assessment of the progress of the treatment. There are many cases where the association of the cancer with specific biomarker is possible. The example for reference may be the two types of colony stimulating factors, G-CSF and M-CSF. M-CSF promotes the production and activation of Monocytes, and G-CSF stimulates the production of granulocytes from stem cells in the bone marrow. G-CSF and GM-CSF, which are produced by recombinant DNA technology, have been approved by the FDA for use in patients with bone marrow depression, such as cancer patients and patients who receive bone marrow transplants. In these patients it is observed that the bone marrow depression is usually associated with intensive chemotherapy or irradiation, and the use of colony stimulating factors avoids the profound and prolonged neutropenia as seen in controls not receiving these compounds, with a corresponding decrease in morbidity and mortality. On the other hand, administration of G-CSF or GM-CSF is expensive and can be associated with severe side effects. The deployment of the new life extending cancer drugs is needed to be measured for its efficacy. The effect of drugs may be detected through the detection of the low amount of the secondary associated biomarkers of the cancer. The various oncologists have different opinion in use of the detection of the immunogenic biomarkers with cancers.

Keywords: B-Cell Signature; Biomarkers; Cancer; Immunogenic; T-Cell Signature.